c-Myc

Myc

c-Myc is the master transcription factor for cell proliferation and is involved in numeroushematological and solidcancers.

Proto-oncogene c-Myc, encoding one of the most important transcription factors, plays a pivotal role in tumor initiation and progression. c-Myc regulates hundreds of disparate target genes that participate numerous biological effects, such as cell proliferation, apoptosis, differentiation, and stem cell self-renewal. c-Myc is one of the four factors used in reprogramming somatic cells to induce pluripotent stem (iPS) cells and is implicated in maintaining cancer stem-like cells (CSCs).

The transcription factor c-Myc is a key mediator of the Notch signaling–regulated T cell differentiation. In a well-established in vitro differentiation model of T lymphocytes from hematopoietic stem cells, Notch1 and 4 directly promotes c-Myc expression; dominant-negative (DN) c-Myc inhibits early T cell differentiation. Moreover, the c-Myc expression activated by Notch signaling increases the expression of survivin, an inhibitor of apoptosis (IAP) protein.

c-Myc gene, as a transcription factor of hTERT, is over expressed in a variety of tumors.c-Myc and hTERT expression in local recurrent gastric cancer tissues is much higher than in primary gastric cancer tissues at the protein and mRNA levels.

c-Myc Inhibitors

10058-F4

Cat. No.: HY-12702

10058-F4 is a **c-Myc** inhibitor that prevents c-Myc-Max dimerization and transactivation of c-Myc target gene expression.



Purity: 99.85%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg

10074-G5

Cat. No.: HY-100996

10074-G5 is an inhibitor of **c-Myc-Max** dimerization with an IC_{50} of 146 μM.



Purity: 96.81%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

APTO-253

(LOR-253; LT-253)

Cat. No.: HY-16291

APTO-253 is a small molecule that inhibits **c-Myc** expression, stabilizes G-quadruplex DNA, and induces cell cycle arrest and **apoptosis** in acute myeloid leukemia cells. APTO-253 mediates anticancer activity through induction of the **Krüppel-like factor 4 (KLF4)** tumor suppressor.



Purity: 96.80%
Clinical Data: Phase 1
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

IZCZ-3

Cat. No.: HY-111411

IZCZ-3 is a potent **c-MYC transcription** inhibitor with antitumor activity.



Purity: 99.45%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

KJ Pyr 9

Cat. No.: HY-19735

KJ Pyr 9 is an inhibitor of **MYC** with a K_d of 6.5 nM in in vitro assay.



Purity: 99.25%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 50 mg, 100 mg

KSI-3716

Cat. No.: HY-12703

KSI-3716 is a potent **c-Myc** inhibitor that blocks c-MYC/MAX binding to target gene promoters. KSI-3716 is an effective intravesical chemotherapy agent for bladder cancer.



Purity: 98.55%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

Lusianthridin

Cat. No.: HY-121418

Lusianthridin, a pure compound from Dendrobium venustum, have an anti-migratory effect. Lusianthridin enhances c-Myc degradation through the inhibition of Src-STAT3 signaling.



Purity: >98%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg

ML327

Cat. No.: HY-103038

ML327 is a blocker of **MYC** which can also de-repress E-cadherin transcription and reverse Epithelial-to-Mesenchymal Transition (EMT).



Purity: 98.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 1 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MYCi361

(NUCC-0196361)

Cat. No.: HY-129600

MYCi361 (NUCC-0196361) is a **MYC** inhibitor with the K_d of 3.2 μM for binding to MYC. MYCi361 (NUCC-0196361) suppresses tumor growth and enhances anti-PD1 immunotherapy.



Purity: 99.42%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

MYCi975

(NUCC-0200975)

Cat. No.: HY-129601

MYCi975 (NUCC-0200975) is an orally active **MYC** inhibitor, which disrupts MYC/MAX interaction, promotes MYC T58 phosphorylation and MYC degradation, and impairs MYC driven gene expression.



Purity: 99.19%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 5 mg, 10 mg

MYCMI-6

(NSC354961)

Cat. No.: HY-124675

MYCMI-6 (NSC354961) is a potent and selective endogenous **MYC:MAX** protein interactions inhibitor. MYCMI-6 blocks MYC-driven transcription and binds selectively to the MYC bHLHZip domain with a K_d of 1.6μM.



Purity: 95.58%
Clinical Data: No Development Reported
Size: 5 mg, 10 mg, 50 mg, 100 mg

Mycro 3

Cat. No.: HY-100669

Mycro 3 is a potent and selective **c-Myc** inhibitor in whole cell assays.



Purity: 99.33%
Clinical Data: No Development Reported
Size: 10 mM × 1 mL, 2 mg, 5 mg, 10 mg, 25 mg, 50 mg, 100 mg

sAJM589

Cat. No.: HY-122683

sAJM589 is a **Myc** inhibitor which potently disrupts the Myc-Max heterodimer with an IC_{50} of 1.8 μM.



Purity: 99.65%
Clinical Data:
Size: 10 mM × 1 mL, 5 mg, 10 mg

Stauprimide

Cat. No.: HY-N6747

Stauprimide is a staurosporine analog that promotes embryonic stem cell (ESC) differentiation.



Purity: >98.0%
Clinical Data: No Development Reported
Size: 1 mg, 5 mg